Interleukin-1 beta synthesis and expression pathway (IL-1β synthesis pathway)

The Interleukin-1 beta (IL-1β) synthesis and expression pathway is a fundamental component of the innate immune system, governing the production and release of a potent pro-inflammatory cytokine (NIH, Wikipedia). This pathway is characterized by a two-signal requirement: a 'priming' signal that induces the transcription of the IL1B gene via NF-κB, and an 'activation' signal that triggers the assembly of the inflammasome complex, such as NLRP3 (BioTechniques, NIH). The inflammasome activates Caspase-1, which then cleaves the inactive pro-IL-1β precursor into its mature, bioactive form (NIH, BioTechniques). Once secreted, mature IL-1β binds to the IL-1 receptor (IL-1R1), initiating a signaling cascade that promotes the expression of adhesion molecules, chemokines, and secondary cytokines like IL-6 (NIH, Frontiers in Immunology). Dysregulation of this pathway leads to excessive inflammation and is implicated in a wide range of conditions, including autoinflammatory syndromes, gout, and cardiovascular diseases like atherosclerosis (NIH, Frontiers in Immunology). Therapeutic strategies targeting this pathway include monoclonal antibodies that neutralize IL-1β, receptor antagonists that block signaling, and emerging small-molecule inhibitors of the NLRP3 inflammasome or Caspase-1 (NIH, Wikipedia).

Other names

IL-1 beta production pathwayIL-1 beta processing pathwayInflammasome-mediated IL-1 beta synthesisIL-1 signaling pathwayIL-1 beta pathway

Drugs targeting this pathway function through several mechanisms: neutralizing the mature IL-1β cytokine (e.g., canakinumab), competitively inhibiting the IL-1 receptor (e.g., anakinra), or preventing the synthesis of the mature cytokine by inhibiting the NLRP3 inflammasome (e.g., dapansutrile) or Caspase-1 (e.g., belnacasan).